Skip to main content

Table 2 Inflammatory biomarkers and hepatic characteristic changes after 12 week of intervention

From: Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

characteristicBaselineAfter 12 weekP aChange (%)P b
hs-CRP (ng/dL)
 Curcumin group5647.1 ± 3858.44653.8 ± 4243.80.12− 993.3 ± 385.40.660
 Placebo group6705.0 ± 4794.95310.2 ± 5071.70.53− 1394.8 ± 276.8
TNF-α (pg/mL)
 Curcumin group19.34 ± 5.416.51 ± 4.5< 0.001−2.83 ± 0.90.972
 Placebo group18.63 ± 2.216.54 ± 2.10.02−2.09 ± 0.1
NF-κB
 Curcumin group2.07 ± 1.031.65 ± 0.630.044−0.49 ± 0.290.539
 Placebo group2.13 ± 0.922.03 ± 0.510.209− 0.26 ± 0.20
ALT (IU/L)
 Curcumin group26.54 ± 15.4620.82 ± 10.09< 0.001−5.58 ± 14.60.778
 Placebo group28.02 ± 13.0621.2 ± 7.72< 0.001−6.82 ± 15.8
AST (IU/L)
 Curcumin group17.78 ± 9.5614.75 ± 7.45< 0.001−2.76 ± 7.540.728
 Placebo group16.23 ± 5.6612.77 ± 4.05< 0.001−3.46 ± 5.43 
Fibrosis (kPa)
 Curcumin group6.98 ± 2.426.2 ± 2.38< 0.001−0.78 ± 0.890.364
 Placebo group6.52 ± 2.386.02 ± 1.80.095−0.49 ± 1.15
Steatosis (db/m)
 Curcumin group298.35 ± 29.5282.65 ± 40.090.015−15.69 ± 30.720.112
 Placebo group315.18 ± 35.69283.18 ± 49.830.001−32 ± 34.3
  1. NAFLD none-alcoholic Fatty Liver Disease, BMI: body mass index, TNF tumor necrosis factor, NF-kB Nuclear factor kappa B, hs-CRP high sensitive C reactive protein, ALT Alanine aminotransferase, AST Aspartate aminotransferase
  2. aP values indicate comparison within groups
  3. bP values indicate comparison between the changes of each variable between 2 groups